EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

December 13, 2015

???This agreement represents a significant milestone for EpiCept and welcome news for patients suffering from AML in Europe, who will now be able to readily access this life saving medicine once launched,??? remarked Jack Talley, president and CEO of EpiCept. ???Meda's strengths and assets are exactly those that we sought from the start of our selection process, including vast marketing and distribution coverage throughout Europe and a deep knowledge of and relationships within the oncology space. From a corporate perspective, we believe this agreement provides us with the resources needed to continue our growth as a commercial enterprise with a host of near-term and long-term value drivers. It also will allow us to more fully focus on preparing our new drug application to the U.S. Food and Drug Administration for Ceplene later this year, and on expanding its use in other hematologic malignancies. We look forward to working closely with Meda in the commercialization of Ceplene.???

SOURCE EpiCept Corporation